Structure, function and amyloidogenic propensity of apolipoprotein A-I

Amyloid

Volumn 13, Issue 4, 2006, Pages 191-205

  Obici, Laura ^a   Franceschini, Guido ^b   Calabresi, Laura ^b   Giorgetti, Sofia ^a,b,c   Stoppini, Monica ^c   Merlini, Giampaolo ^a,b,c   Bellotti, Vittorio ^a,b,c,d  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d Department of Biochemistry ^*  (Italy)

Author keywords

Amyloidosis; Apolipoprotein A I; HDL; Misfolding

Indexed keywords

AMYLOID; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; MUTANT PROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; AMYLOIDOGENESIS; AMYLOIDOSIS; EXON; GENE MUTATION; GENETIC CODE; HUMAN; HYPOLIPOPROTEINEMIA; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN QUATERNARY STRUCTURE; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTEIN TERTIARY STRUCTURE; REVIEW; STRUCTURE ANALYSIS; ULTRASTRUCTURE; WILD TYPE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMYLOID; APOLIPOPROTEIN A-I; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN CONFORMATION; PROTEIN FOLDING;

EID: 33750394045     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.1080/13506120600960288     Document Type: Review

References (90)

1. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, Sipe JD. Amyloid: Toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid J Protein Folding Disord 2005;12:1-4.
2. Gallo G, Wisniewski T, Choimiura NH, Ghiso J, Frangione B. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 1994;145:526-530.
3. Hatters DM, Lawrence LJ, Howlett GJ. Sub-micellar phospholipid accelerates amyloid formation by apolipoprotein C-II. FEBS Lett 2001;494:220-224.
4. Rocken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 2002;440:111-122.
5. Benson MD. Ostertag revisited: the inherited systemic amyloidoses without neuropathy. Amyloid J Protein Folding Disord 2005;12:75-87.
6. Gregorini G, Izzi C, Obici L, Tardanico R, Rocken C, Viola BF, Capistrano M, Donadei S, Biasi L, Scalvini T, Merlini G, Scolari F. Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis. J Am Soc Nephrol 2005;16:3680-3686.
7. Obici L, Bellotti V, Mangione P, Stoppini M, Arbustini E, Verga L, Zorzoli I, Anesi E, Zanotti G, Campana C, Vigano M, Merlini G. The new apolipoprotein A-I variant Leu174Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. Am J Pathol 1999;155:695-702.
8. Hamidi Asl L, Liepnieks JJ, Hamidi Asl K, Uemichi T, Moulin G, Desjoyaux E, Loire R, Delpech M, Grateau G, Benson MD. Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1. Am J Pathol 1999;154:221-227.
9. de Sousa MM, Vital C, Ostler D, Fernandes R, Pouget-Abadie J, Carles D, Saraiva MJ. Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. Am J Pathol 2000;156:1911-1917.
10. Schrepferman CG, Lester DR, Sandlow JI. Testicular amyloid deposition as a cause of secondary azoospermia. Urology 2000;55:145-146.
11. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. New Engl J Med 2003;349:583-596.
12. Elimova E, Kisilevsky R, Szarek WA, Ancsin JB. Amyloido-genesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. FASEB J 2004;18:1749-1751.
13. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211-228.
14. Ikewaki K, Rader DJ, Schaefer JR, Fairwell T, Zech LA, Brewer HB Jr. Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J Lipid Res 1993;34:2207-2215.
15. Pagani F, Sidoli A, Giudici GA, Barenghi L, Vergani C, Baralle FE. Human apolipoprotein A-I gene promoter polymorphism: association with hyperalphalipoproteinemia. J Lipid Res 1990;31:1371-1377.
16. Barre DE, Guerra R, Verstraete R, Wang Z, Grundy SM, Cohen JC. Genetic analysis of a polymorphism in the human apolipoprotein A-I gene promoter: effect on plasma HDL-cholesterol levels. J Lipid Res 1994;35:1292-1296.
17. Brinton EA. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein AI and lowers hepatic lipase activity without lowering catabolic rate. Arterioscler Thromb Vasc Biol 1996;16:431-440.
18. Zhang X, Jiao JJ, Bhavnani B, Tam SP. Regulation of human apolipoprotein A-I gene expression by equine estrogens. J Lipid Res 2001;42:1789-1880.
19. Harnish DC, Evans MJ, Scichitano MS, Bhat RA, Karathanasis SK. Estrogen regulation of the apolipoprotein Al promoter through transcription factor sharing. J Biol Chem 1998;273:9270-9278.
20. Wehmeier K, Beers A, Haas MJ, Wong NC, Steinmeyer A, Zugel U, Mooradian AD. Inhibition of apolipoprotein AI gene expression by 1,25-dihydroxyvitamin D3. Biochim Biophys Acta 2005;1737:16-26.
21. Mooradian AD, Haas MJ, Wadud K. Ascorbic acid and alpha-tocopherol down-regulate apolipoprotein A-I gene expression in HepG2 and Caco-2 cell lines. Metabolism 2006;55:159-167.
22. Law SW, Brewer HB Jr. Nucleotide sequence and the encoded amino acids of human apolipoprotein A-I mRNA. Proc Natl Acad Sci USA 1984;81:66-70.
23. Scanu AM, Byrne RE, Edelstein C. Proteolytic events affecting plasma apolipoproteins at the co- and post-translational levels and after maturation. J Lipid Res 1984;25:1593-1602.
24. Batal R, Tremblay M, Krimbou L, Mamer O, Davignon J, Genest J Jr, Cohn JS. Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I. Arterioscler Thromb Vasc Biol 1998;18:655-664.
25. Chisholm JW, Burleson ER, Shelness GS, Parks JS. ApoA-I secretion from HepG2 cells: evidence for the secretion of both lipid-poor apoA-I and intracellularly assembled nascent HDL. J Lipid Res 2002;43:36-44.
26. Kiss RS, McManus DC, Franklin V, Tan WL, McKenzie A, Chimini G, Marcel YL. The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1-dependent and - independent pathways. J Biol Chem 2003;278:10119-10127.
27. Hamilton RL, Moorehouse A, Havel RJ. Isolation and properties of nascent lipoproteins from highly purified rat hepatocytic Golgi fractions. J Lipid Res 1991;32:529-543.
28. Tsujita M, Wu CA, Abe-Dohmae S, Usui S, Okazaki M, Yokoyama S. On the hepatic mechanism of HDL assembly by the ABCA1/apoA-I pathway. J Lipid Res 2005;46:154-162.
29. Schaefer EJ, Jenkins LL, Brewer HB Jr. Human chylomicron apolipoprotein metabolism. Biochem Biophys Res Commun 1978;80:405-412.
30. Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta 2000;1529:245-256.
31. Sorci-Thomas MG, Thomas MJ. The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc Med 2002;12:121-128.
32. de Beer MC, Durbin DM, Cai L, Jonas A, de Beer FC, van der Westhuyzen DR. Apolipoprotein A-I conformation markedly influences HDL interaction with scavenger receptor BI. J Lipid Res 2001;42:309-313.
33. Trigatti BL, Krieger M, Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:1732-1738.
34. Rye KA, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004;24:421-428.
35. Lawn RM, Wade DP, Couse TL, Wilcox JN. Localization of human ATP-binding cassette transporter 1 (ABC1) in normal and atherosclerotic tissues. Arterioscler Thromb Vasc Biol 2001;21:378-385.
36. Eckhardt ER, Cai L, Sun B, Webb NR, van der Westhuyzen DR. High density lipoprotein uptake by scavenger receptor SR-BII. J Biol Chem 2004;279:14372-14381.
37. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne E, Pineau T, Georgeaud V, Walker JE, Terce F, Collet X, Perret B, Barbaras R. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003;421:75-79.
38. Glass CK, Pittman RC, Keller GA, Steinberg D. Tissue sites of degradation of apolipoprotein A-I in the rat. J Biol Chem 1983;258:7161-7167.
39. Moestrup SK, Kozyraki R. Cubilin, a high-density lipoprotein receptor. Curr Opin Lipidol 2000;11:133-140.
40. Kozyraki R, Fyfe J, Kristiansen M, Gerdes C, Jacobsen C, Cui S, Christensen EI, Aminoff M, de la Chapelle A, Krahe R, Verroust PJ, Moestrup SK. The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat Med 1999;5:656-661.
41. Braschi S, Neville TA, Vohl MC, Sparks DL. Apolipoprotein A-I charge and conformation regulate the clearance of reconstituted high density lipoprotein in vivo. J Lipid Res 1999;40:522-532.
42. Calabresi L, Meng QH, Castro GR, Marcel YL. Apolipoprotein A-I conformation in discoidal particles: evidence for alternate structures. Biochemistry 1993;32:6477-6484.
43. Segrest JP, De Loof H, Dohlman JG, Brouillette CG, Anantharamaiah GM. Amphipathic helix motif: classes and properties. Proteins 1990;8:103-117.
44. Borhani DW, Rogers DP, Engler JA, Brouillette CG. Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc Natl Acad Sci USA 1997;94:12291-12296.
45. Ajees AA, Anantharamaiah GM, Mishra VK, Hussain MM, Murthy HM. Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci USA 2006;103:2126-2131.
46. Wang G, Sparrow JT, Cushley RJ. The helix-hinge-helix structural motif in human apolipoprotein A-I determined by NMR spectroscopy. Biochemistry 1997;36:13657-13666.
47. Bhat S, Sorci-Thomas MG, Alexander ET, Samuel MP, Thomas MJ. Intermolecular contact between globular N-terminal fold and C-terminal domain of ApoA-I stabilizes its lipid-bound conformation: studies employing chemical cross-linking and mass spectrometry. J Biol Chem 2005;280:33015-33025.
48. Brouillette CG, Anantharamaiah GM, Engler JA, Borhani DW. Structural models of human apolipoprotein A-I: a critical analysis and review. Biochim Biophys Acta 2001;1531:4-46.
49. Gross E, Peng DQ, Hazen SL, Smith JD. A novel folding intermediate state for apolipoprotein A-I: role of the amino and carboxy termini. Biophys J. 2006;90:1362-1370.
50. Gursky O, Atkinson D. Thermal unfolding of human high-density apolipoprotein A-1: implications for a lipid-free molten globular state. Proc Natl Acad Sci USA 1996;93:2991-2995.
51. Marcel YL, Kiss RS. Structure-function relationships of apolipoprotein A-I: a flexible protein with dynamic lipid associations. Curr Opin Lipidol 2003;14:151-157.
52. Scott BR, McManus DC, Franklin V, McKenzie AG, Neville T, Sparks DL, Marcel YL. The N-terminal globular domain and the first class A amphipathic helix of apolipoprotein A-I are important for lecithin:cholesterol acyltransferase activation and the maturation of high density lipoprotein in vivo. J Biol Chem 2001;276:48716-48724.
53. Burgess JW, Frank PG, Franklin V, Liang P, McManus DC, Desforges M, Rassart E, Marcel YL. Deletion of the C-terminal domain of apolipoprotein A-I impairs cell surface binding and lipid efflux in macrophage. Biochemistry 1999;38:14525-14533.
54. Van den Berg B, Wain R, Dobson CM, Ellis RJ. Macromolecular crowding perturbs protein refolding kinetics: implications for folding inside the cell. EMBO J 2000;19:3870-3875.
55. Bhat S, Zabalawi M, Willingham MC, Shelness GS, Thomas MJ, Sorci-Thomas MG. Quality control in the apoA-I secretory pathway: deletion of apoA-I helix 6 leads to the formation of cytosolic phospholipid inclusions. J Lipid Res 2004;45:1207-1220.
56. von Eckardstein A, Funke H, walter M, Altland K, Benninghoven A, Assman G. Structural analysis of human apolipoproteinA-I variants. J Biol Chem 1990;265:8610-8617.
57. Frank PG, Marcel YL. Apolipoprotein A-I: structure-function relatioship. J Lipid Res 2000;41:853-872.
58. Wiesgraber KH, Bersot TP, Mahley RW, Franceschini G, Sirtori CR. A-I Milano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoprotein. J Clin Invest 1980;66:901-907.
59. Sorci-Thomas MG, Thomas M, Curtiss L, Landrum M. Single repeat deletion in apoA-I blocks cholesterol esterification and results in rapid catabolism of Δ6 and wild-type apoA-I in transgenic mice. J Biol Chem 2000;275:12156-12163.
60. Nichols WC, Dwulet FE, Liepnieks J, Benson MD. Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. Biochem Biophys Res Commun 1988;156:762-768.
61. Soutar AK, Hawkins PN, Vigushin DM, Tennent GA, Booth SE, Hutton T, Nguyen O, Totty NF, Feest TG, Hsuan JJ, Pepys M. Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci USA 1992;89:7389-7393.
62. Booth DR, Tan SY, Booth SE, Hsuan JJ, Totty NF, Nguyen O, Hutton T, Vigushin DM, Tennent GA, Hutchinson WL, Thompson N, Soutar AK, Hawkins PN, Pepys M. A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. QJM 1995;88:695-702.
63. Booth DR, Tan SY, Booth SE, Tennent GA, Hutchinson WL, Hsuan JJ, Totty NF, Truong O, Soutar AK, Hawkins PN, Bruguera M, Caballeria J, Sole M, Campistol JM, Pepys MB. Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. J Clin Invest 1996;97:2714-2721.
64. Persey MR, Booth DR, Booth SE, van Zyl-Smit R, Adams BK, Fattaar AB, Tennent GA, Hawkins PN, Pepys MB. Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. Kidney Int 1998;53:276-281.
65. Pepys MB, Tennent GA, Booth DR, Bellotti V, Lovat LB, Tan SY, Persey MR, Hutchinson WL, Booth SE, Madhoo S, Soutar AK, Hawkins PN, Van Zyl-Smit R, Campistol JM, Fraser PE, Radford SE, Robinson CV, Sunde M, Serpell LC, Blake CC. Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy. Ciba Found Symp 1996;199:73-81.
66. Obici L, Palladini G, Giorgetti S, Bellotti V, Gregorini G, Arbustini E, Verga L, Marciano S, Donadei S, Perfetti V, Calabresi L, Bergonzi C, Scolari F and Merlini G. Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology 2004;126:1416-1422.
67. Coriu D, Dispenzieri A, Stevens FJ, Murphy CL, Wang S, Weiss DT, Solomon A. Hepatic amyloidosis resulting from deposition of the apolipoprotein A-I variant Leu75Pro. Amyloid J Protein Folding Disord 2003;10:215-223.
68. Murphy CL, Wang S, Weaver K, Gertz MA, Weiss DT, Solomon A. Renal apolipoprotein A-I amyloidosis associated with a novel mutant Leu64Pro. Am J Kidney Dis 2004;44:1103-1109.
69. Hamidi Asl K, Liepnieks JJ, Nakamura M, Parker F, Benson MD. A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis. Biochem Biophys Res Commun 1999;257:584-588.
70. Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. New Engl J Med 2002;346:1786-1791.
71. Chou PY, Fasman GD. Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol 1978;47:145-148.
72. Mangione P, Sunde M, Giorgetti S, Stoppini M, Esposito G, Gianelli L, Obici L, Asti L, Andreola A, Viglino P, Merlini G, Bellotti V. Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. Protein Sci 2001;10:187-199.
73. Relini A, Rolandi R, Bolognesi M, Aboudan M, Merlini G, Bellotti V, Gliozzi A. Ultrastructural organization of ex vivo amyloid fibrils formed by the apolipoprotein A-I Leu174Ser variant: an atomic force microscopy study. Biochim Biophys Acta 2004;1690:33-41.
74. Serpell LC, Sunde M, Benson MD, Tennent GA, Pepys MB, Fraser PE. The protofilament substructure of amyloid fibrils. J Mol Biol 2000;300:1033-1039.
75. Ji Y, Jonas A. Properties of an N-terminal proteolytic fragment of apolipoprotein AI in solution and in reconstituted high density lipoproteins. J Biol Chem 1995;270:11290-11297.
76. Roberts LM, Ray MJ, Shih TW, Hayden H, Reader MM, Brouillette CG. Structural analysis of apolipoprotein A-I: limited proteolysis of methionine-reduced and oxidized lipid-free and lipid-bound human apo A-I. Biochemistry 1997;36:7615-7624.
77. Rogers DP, Roberts LM, Lebowitz J, Engler JA, Brouillette CG. Structural analysis of apolipoprotein A-I: effects of amino- and carboxy-terminal deletions on the lipidfree structure. Biochemistry 1998;37:945-955.
78. Eberini I, Calabresi L, Wait R, Tedeschi G, Pirillo A, Puglisi L, Sirtori CR, Gianazza E. Macrophage metalloproteinases degrade high-density lipoprotein-associated apolipoprotein A-I at both the N- and C-termini. Biochem J 2002;362:627-634.
79. McManus DC, Scott BR, Franklin V, Sparks DL, Marcel YL. Proteolytic degradation and impaired secretion of an apolipoprotein A-I mutant associated with dominantly inherited hypoalphalipoproteinemia. J Biol Chem 2001;276:21292-21302.
80. Miettinen HE, Jauhiainen M, Gylling H, Ehnholm S, Palomaki A, Miettinen TA, Kontula K. Apolipoprotein A-IFIN (Leu159→Arg) mutation affects lecithin cholesterol acyltransferase activation and subclass distribution of HDL but not cholesterol efflux from fibroblasts. Arterioscler Thromb Vasc Biol 1997;17:3021-3032.
81. Bellotti V, Obici L, Kisilevsky R, Merlini G. Anatomic and clinical clues to in vivo mechanisms of amyloidogenesis. In: Sipe JD, editor. Amyloid proteins. The beta sheet conformation and disease. Weinheim: Wiley-VCH; 2005. pp 2-48.
82. Andreola A, Bellotti V, Giorgetti S, Mangione P, Obici L, Stoppini M, Torres J, Monzani E, Merlini G, Sunde M. Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein A-I. J Biol Chem 2003;278:2444-2451.
83. Westermark P, Mucchiano G, Marthin T, Johnson KH, Sletten K. Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. Am J Pathol 1995;147:1186-1192.
84. Mucchiano GI, Haggqvist B, Sletten K, Westermark P. Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta. J Pathol 2001;193:270-275.
85. Amarzguioui M, Mucchiano G, Haggqvist B, Westermark P, Kavlie A, Sletten K, Prydz H. Extensive intimal apolipoprotein A1-derived amyloid deposits in a patient with an apolipoprotein A1 mutation. Biochem Biophys Res Commun 1998;242:534-539.
86. Mucchiano GI, Jonasson L, Haggqvist B, Einarsson E, Westermark P. Apolipoprotein A-I-derived amyloid in atherosclerosis. Its association with plasma levels of apolipoprotein A-I and cholesterol. Am J Clin Pathol 2001;115:298-303.
87. Johnson KH, Sletten K, Hayden DW, O'Brien TD, Roertgen KE, Westermark P. Pulmonary vascular amyloidosis in aged dogs. A new form of spontaneously occurring amyloidosis derived from apolipoprotein A-I. Am J Pathol 1992;141:1013-1019.
88. Rader DJ, Gregg RE, Meng MS, Schaefer JR, Zech LA, Benson MD, Brewer HB Jr. In vivo metabolism of a mutant apolipoprotein, apoA-I Iowa, associated with hypoalphalipo-proteinemia and hereditary systemic amyloidosis. J Lipid Res 1992;33:755-763.
89. Genschel J, Haas R, Propsting MJ, Schmidt HH. Apolipoprotein A-I induced amyloidosis. FEBS Lett 1998;430:145-149.
90. Almeida MR, Gales L, Damas AM, Cardoso I, Saraiva MJ. Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr Drug Targets CNS Neurol Disord 2005;5:587-596.